The FY19 Defense Appropriation provides $130 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).
FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.
Applications submitted to the FY19 BCRP must address one or more of the following overarching challenges:
- · Prevent breast cancer (primary prevention)
- · Identify determinants of breast cancer initiation, risk, or susceptibility
- · Distinguish deadly from non-deadly breast cancers
- · Conquer the problems of overdiagnosis and overtreatment
- · Identify what drives breast cancer growth; determine how to stop it
- · Identify why some breast cancers become metastatic
- · Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- · Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
- · Eliminate the mortality associated with metastatic breast cancer